Poolbeg Pharma (LON:POLB) Shares Up 2.9% – What’s Next?

Poolbeg Pharma PLC (LON:POLB)’s stock price was up 2.9% on Wednesday . The company traded as high as GBX 7.18 and last traded at GBX 7.10. Approximately 301,551 shares traded hands during trading, a decline of 81% from the average session volume of 1,622,017 shares. The stock had previously closed at GBX 6.90.

Wall Street Analyst Weigh In

Separately, Shore Capital Group restated a “house stock” rating on shares of Poolbeg Pharma in a report on Tuesday, June 16th.

Poolbeg Pharma Price Performance

The stock has a market capitalization of £50.06 million, a price-to-earnings ratio of -7.55 and a beta of 1.82. The company has a 50 day moving average of GBX 6.24 and a 200 day moving average of GBX 5.03.

Poolbeg Pharma (LON:POLB) last released its earnings results on Tuesday, April 28th. The company reported GBX (0.94) earnings per share (EPS) for the quarter. On average, research analysts forecast that Poolbeg Pharma PLC will post -0.68 earnings per share for the current fiscal year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.